Molecular pathology of thyroid cancer: diagnostic and clinical implications

Sobrinho-Simoes, 2008, Intragenic mutations in thyroid cancer, Endocrinology and Metabolism Clinics of North America, 37, 333, 10.1016/j.ecl.2008.02.004 Davies, 2006, Increasing incidence of thyroid cancer in the United States, 1973–2002, JAMA: The Journal of the American Medical Association, 295, 2164, 10.1001/jama.295.18.2164 2004 Santoro, 2002, Molecular mechanisms of RET activation in human cancer, Annals of the New York Academy of Sciences, 963, 116, 10.1111/j.1749-6632.2002.tb04102.x Treanor, 1996, Characterization of a multicomponent receptor for GDNF, Nature, 382, 80, 10.1038/382080a0 Nikiforov, 2008, Thyroid carcinoma: molecular pathways and therapeutic targets, Modern Pathology, 21, S37, 10.1038/modpathol.2008.10 Nikiforov, 1997, Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children, Cancer Research, 57, 1690 Viglietto, 1995, RET/PTC oncogene activation is an early event in thyroid carcinogenesis, Oncogene, 11, 1207 Sugg, 1998, Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia, The Journal of Clinical Endocrinology and Metabolism, 83, 4116 Jhiang, 1996, Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas, Endocrinology, 137, 375, 10.1210/endo.137.1.8536638 Santoro, 1996, Development of thyroid papillary carcinomas secondary to tissue- specific expression of the RET/PTC1 oncogene in transgenic mice, Oncogene, 12, 1821 Powell, 1998, The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids, Cancer Research, 58, 5523 Ito, 1993, In vitro irradiation is able to cause RET oncogene rearrangement, Cancer Research, 53, 2940 Mizuno, 1997, Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis, Oncogene, 15, 1455, 10.1038/sj.onc.1201313 Unger, 2006, RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH, British Journal of Cancer, 94, 1472, 10.1038/sj.bjc.6603109 Zhu, 2006, Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity, The Journal of Clinical Endocrinology and Metabolism, 91, 3603, 10.1210/jc.2006-1006 Santoro, 2002, RET activation and clinicopathologic features in poorly differentiated thyroid tumors, The Journal of Clinical Endocrinology and Metabolism, 87, 370, 10.1210/jcem.87.1.8174 Adeniran, 2006, Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas, The American Journal of Surgical Pathology, 30, 216, 10.1097/01.pas.0000176432.73455.1b Ricarte Filho, 2008, Molecular profiling of poorly differentiated and anaplastic thyroid cancers by mass spectrometry with a thyroid cancer-specific platform reveals distinct patterns of oncogenic activation, American Thyroid Association Takahashi, 2001, The GDNF/RET signaling pathway and human diseases, Cytokine & Growth Factor Reviews, 12, 361, 10.1016/S1359-6101(01)00012-0 Hayashi, 2000, Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor, Oncogene, 19, 4469, 10.1038/sj.onc.1203799 Kimura, 2003, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, Cancer Research, 63, 1454 Frattini, 2004, Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer, Oncogene, 10.1038/sj.onc.1207980 Soares, 2003, BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC, Oncogene, 22, 4578, 10.1038/sj.onc.1206706 Suarez, 1988, Detection of activated ras oncogenes in human thyroid carcinomas, Oncogene, 2, 403 Namba, 1990, Point mutations of ras oncogenes are an early event in thyroid tumorigenesis, Molecular Endocrinology (Baltimore, Md.), 4, 1474, 10.1210/mend-4-10-1474 Zhu, 2003, Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations, American Journal of Clinical Pathology, 120, 71, 10.1309/ND8D9LAJTRCTG6QD Daum, 1994, The ins and outs of Raf kinases, Trends in Biochemical Sciences, 19, 474, 10.1016/0968-0004(94)90133-3 Peyssonnaux, 2001, The Raf/MEK/ERK pathway: new concepts of activation, Biologie cellulaire, 93, 53, 10.1016/S0248-4900(01)01125-X Reuter, 1995, Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators, The Journal of Biological Chemistry, 270, 7644, 10.1074/jbc.270.13.7644 Mitsutake, 2006, BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis, Endocrinology, 147, 1014, 10.1210/en.2005-0280 Dhillon, 2004, Oncogenic B-Raf mutations: crystal clear at last, Cancer Cell, 5, 303, 10.1016/S1535-6108(04)00087-X Ciampi, 2005, Oncogenic AKAP9–BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer, The Journal of Clinical Investigation, 115, 94, 10.1172/JCI23237 Xing, 2005, BRAF mutation in thyroid cancer, Endocrine-Related Cancer, 12, 245, 10.1677/erc.1.0978 Trovisco, 2004, BRAF mutations are associated with some histological types of papillary thyroid carcinoma, The Journal of Pathology, 202, 247, 10.1002/path.1511 Nikiforova, 2003, BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas, The Journal of Clinical Endocrinology and Metabolism, 88, 5399, 10.1210/jc.2003-030838 Fukushima, 2003, BRAF mutations in papillary carcinomas of the thyroid, Oncogene, 22, 6455, 10.1038/sj.onc.1206739 Namba, 2003, Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers, The Journal of Clinical Endocrinology and Metabolism, 88, 4393, 10.1210/jc.2003-030305 Xu, 2003, High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines, Cancer Research, 63, 4561 Cohen, 2003, BRAF mutation in papillary thyroid carcinoma, Journal of the National Cancer Institute, 95, 625, 10.1093/jnci/95.8.625 Xing, 2005, BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer, The Journal of Clinical Endocrinology and Metabolism, 90, 6373, 10.1210/jc.2005-0987 Puxeddu, 2004, BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas, The Journal of Clinical Endocrinology and Metabolism, 89, 2414, 10.1210/jc.2003-031425 Xing, 2007, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications, Endocrine Reviews, 28, 742, 10.1210/er.2007-0007 Romei, 2008, BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer, Endocrine-Related Cancer, 15, 511, 10.1677/ERC-07-0130 Mian, 2008, Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake, Clinical Endocrinology, 68, 108, 10.1111/j.1365-2265.2007.03008.x Durante, 2007, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism, The Journal of Clinical Endocrinology and Metabolism, 92, 2840, 10.1210/jc.2006-2707 Riesco-Eizaguirre, 2006, The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane, Endocrine-Related Cancer, 13, 257, 10.1677/erc.1.01119 Knauf, 2005, Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation, Cancer Research, 65, 4238, 10.1158/0008-5472.CAN-05-0047 Leboeuf, 2008, BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines, The Journal of Clinical Endocrinology and Metabolism, 93, 2194, 10.1210/jc.2007-2825 Kroll, 2000, PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma, Science, 289, 1357, 10.1126/science.289.5483.1357 Marques, 2002, Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas, The Journal of Clinical Endocrinology and Metabolism, 87, 3947 Cheung, 2003, Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas, The Journal of Clinical Endocrinology and Metabolism, 88, 354, 10.1210/jc.2002-021020 Gregory, 2004, The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition, Oncogene, 23, 3634, 10.1038/sj.onc.1207399 Au, 2006, PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth, Endocrinology, 147, 367, 10.1210/en.2005-0147 Lacroix, 2005, Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations, The American Journal of Pathology, 167, 223, 10.1016/S0002-9440(10)62967-7 Nikiforova, 2003, RAS point mutations and PAX8-PPARgamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma, The Journal of Clinical Endocrinology and Metabolism, 88, 2318, 10.1210/jc.2002-021907 Sahin, 2005, PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value, The Journal of Clinical Endocrinology and Metabolism, 90, 463, 10.1210/jc.2004-1203 Marques, 2004, Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours, British Journal of Cancer, 91, 732, 10.1038/sj.bjc.6601989 Esapa, 1999, Prevalence of Ras mutations in thyroid neoplasia, Clinical Endocrinology, 50, 529, 10.1046/j.1365-2265.1999.00704.x Vitagliano, 2006, Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas, Oncogene, 25, 5467, 10.1038/sj.onc.1209527 Knauf, 2006, Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints, The Journal of Biological Chemistry, 281, 3800, 10.1074/jbc.M511690200 Saavedra, 2000, The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway, Oncogene, 19, 3948, 10.1038/sj.onc.1203723 Giaretti, 2004, Chromosomal instability, aneuploidy, and gene mutations in human sporadic colorectal adenomas, Cellular Oncology, 26, 301 Castro, 2006, H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid, Oncogene, 25, 4620, 10.1038/sj.onc.1209491 Maximo, 2002, Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors, The American Journal of Pathology, 160, 1857, 10.1016/S0002-9440(10)61132-7 Gasparre, 2007, Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors, Proceedings of the National Academy of Sciences of the United States of America, 104, 9001, 10.1073/pnas.0703056104 Rogounovitch, 2004, Mitochondrial DNA and human thyroid diseases, Endocrine Journal, 51, 265, 10.1507/endocrj.51.265 Maximo, 2005, Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid, British Journal of Cancer, 92, 1892, 10.1038/sj.bjc.6602547 Sobrinho-Simoes, 2005, Hurthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance, International Journal of Surgical Pathology, 13, 29, 10.1177/106689690501300104 Mesa, 2006, Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling, Cancer Research, 66, 6521, 10.1158/0008-5472.CAN-06-0739 Hiltzik, 2006, Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients, Cancer, 106, 1286, 10.1002/cncr.21739 Ryder, 2008, Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer, Endocrine-Related Cancer, 10.1677/ERC-08-0036 Costa, 2008, BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma, Clinical Endocrinology, 68, 618, 10.1111/j.1365-2265.2007.03077.x Garcia-Rostan, 2005, Mutation of the PIK3CA gene in anaplastic thyroid cancer, Cancer Research, 65, 10199, 10.1158/0008-5472.CAN-04-4259 Garcia-Rostan, 2003, Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer, Journal of Clinical Oncology, 21, 3226, 10.1200/JCO.2003.10.130 Santarpia, 2008, Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer, The Journal of Clinical Endocrinology and Metabolism, 93, 278, 10.1210/jc.2007-1076 Hou, 2007, Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer, Clinical Cancer Research, 13, 1161, 10.1158/1078-0432.CCR-06-1125 Samuels, 2004, High frequency of mutations of the PIK3CA gene in human cancers, Science, 304, 554, 10.1126/science.1096502 Samuels, 2005, Mutant PIK3CA promotes cell growth and invasion of human cancer cells, Cancer Cell, 7, 561, 10.1016/j.ccr.2005.05.014 Liu, 2008, Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers, The Journal of Clinical Endocrinology and Metabolism, 93, 3106, 10.1210/jc.2008-0273 Abubaker, 2008, Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population, The Journal of Clinical Endocrinology and Metabolism, 93, 611, 10.1210/jc.2007-1717 Carpten, 2007, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, 448, 439, 10.1038/nature05933 Liaw, 1997, Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome, Nature Genetics, 16, 64, 10.1038/ng0597-64 Harach, 1999, Thyroid pathologic findings in patients with Cowden disease, Annals of Diagnostic Pathology, 3, 331, 10.1016/S1092-9134(99)80011-2 Marsh, 1998, Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation, Genes, Chromosomes & Cancer, 21, 61, 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6 Dahia, 1997, Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors, Cancer Research, 57, 4710 Paes, 2008, Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia, Endocrinology and Metabolism Clinics of North America, 37, 375, 10.1016/j.ecl.2008.01.001 Frisk, 2002, Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer, Genes Chromosomes Cancer, 35, 74, 10.1002/gcc.10098 Gimm, 2000, Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors, The American Journal of Pathology, 156, 1693, 10.1016/S0002-9440(10)65040-7 Ito, 1992, Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland, Cancer Research, 52, 1369 Fagin, 1993, High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas, The Journal of Clinical Investigation, 91, 179, 10.1172/JCI116168 Nikiforov, 1996, Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident, Oncogene, 13, 687 Donghi, 1993, Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland, The Journal of Clinical Investigation, 91, 1753, 10.1172/JCI116385 Gavert, 2007, Beta-Catenin signaling in biological control and cancer, Journal of Cellular Biochemistry, 102, 820, 10.1002/jcb.21505 Polakis, 2007, The many ways of Wnt in cancer, Current Opinion in Genetics & Development, 17, 45, 10.1016/j.gde.2006.12.007 Cetta, 2000, Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study, The Journal of Clinical Endocrinology and Metabolism, 85, 286 von, 1997, Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome, Cancer Research, 57, 2501 Garcia-Rostan, 2001, Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis, The American Journal of Pathology, 158, 987, 10.1016/S0002-9440(10)64045-X Garcia-Rostan, 1999, Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma, Cancer Research, 59, 1811 Rousset, 2008, Molecular diagnosis of differentiated thyroid cancer. Towards the application in clinical practice, Annales d'endocrinologie, 69, 135, 10.1016/j.ando.2008.02.011 Pizzolanti, 2007, Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement, Thyroid, 17, 1109, 10.1089/thy.2007.0008 Chung, 2006, Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area, Clinical Endocrinology, 65, 660, 10.1111/j.1365-2265.2006.02646.x Salvatore, 2004, Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma, The Journal of Clinical Endocrinology and Metabolism, 89, 5175, 10.1210/jc.2003-032221 Cohen, 2004, Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules, Clinical Cancer Research, 10, 2761, 10.1158/1078-0432.CCR-03-0273 Sapio, 2007, Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings, Clinical Endocrinology, 66, 678, 10.1111/j.1365-2265.2007.02800.x Tetzlaff, 2006, Assessing the utility of a mutational assay for B-RAF as an adjunct to conventional fine needle aspiration of the thyroid gland, Advances in Anatomic Pathology, 13, 228, 10.1097/01.pap.0000213044.23823.d3 Bartolazzi, 2001, Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions, Lancet, 357, 1644, 10.1016/S0140-6736(00)04817-0 Bartolazzi, 2008, Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study, The Lancet Oncology, 9, 543, 10.1016/S1470-2045(08)70132-3 Prasad, 2008, Identification of genes differentially expressed in benign versus malignant thyroid tumors, Clinical Cancer Research, 14, 3327, 10.1158/1078-0432.CCR-07-4495 Durand, 2008, Evaluation of gene expression profiles in thyroid nodule biopsy material to diagnose thyroid cancer, The Journal of Clinical Endocrinology and Metabolism, 93, 1195, 10.1210/jc.2007-1571 Hamada, 2005, Diagnostic usefulness of PCR profiling of the differentially expressed marker genes in thyroid papillary carcinomas, Cancer Letters, 224, 289, 10.1016/j.canlet.2004.10.012 Weber, 2005, Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination, The Journal of Clinical Endocrinology and Metabolism, 90, 2512, 10.1210/jc.2004-2028 Cerutti, 2006, Diagnosis of suspicious thyroid nodules using four protein biomarkers, Clinical Cancer Research, 12, 3311, 10.1158/1078-0432.CCR-05-2226 Cerutti, 2004, A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression, The Journal of Clinical Investigation, 113, 1234, 10.1172/JCI19617 Cohen, 2008, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study, Journal of Clinical Oncology, 10.1200/JCO.2007.15.9566 Gupta-Abramson, 2008, Phase II trial of Sorafenib in advanced thyroid cancer, Journal of Clinical Oncology, 10.1200/JCO.2008.16.3279 Sherman, 2008, Motesanib diphosphate in progressive differentiated thyroid cancer, The New England Journal of Medicine, 359, 31, 10.1056/NEJMoa075853 Ladanyi, 2008, Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond, Modern Pathology, 21, S16, 10.1038/modpathol.3801018 Pfister, 2008, Refractory thyroid cancer: a paradigm shift in treatment is not far off, Journal of Clinical Oncology, 10.1200/JCO.2008.17.3682